Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Northland Announces Reset Dividend Rate on Its Cumulative Rate Reset Preferred Shares, Series 1 & Series 2

(NPI) TORONTO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland" or the "Company") (TSX: NPI) today announced that pursuant to the share terms in respect of the Cumulative Rate ...

What are the potential implications of this dividend reset for Northland's capital structure, liquidity, and future growth prospects through 2030? What is the relative attractiveness of Northland's reset dividend compared to peer utilities and other preferred‑share issuers in the Canadian market? How will the 5.70% fixed dividend rate on Series 1 preferred shares influence Northland's common equity valuation and immediate price movement?
Symbol: NPI
Dividends
18 days ago
Read more globenewswire

Investor Alert: Robbins LLP Informs Investors that a Class Action Lawsuit Has Been Filed Against Semler Scientific, Inc.

(NASDAQ:SMLR) SAN DIEGO, Aug. 29, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Semler S...

What is the market's immediate reaction and liquidity impact on SMLR, and how should I adjust my position sizing or hedging strategy? How likely is the class action lawsuit to result in a material adverse event, such as a delisting or significant dilution, and what is the expected timeline? What is the estimated financial exposure and potential settlement amount for Semler Scientific, and how might that affect its valuation?
Symbol: SMLR
Lawsuits
18 days ago
Read more prnewswire

PicoCELA Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

(NASDAQ:PCLA) TOKYO, Aug. 30, 2025 /PRNewswire/ -- PicoCELA Inc. ("PicoCELA" or the "Company") (Nasdaq: PCLA), a Tokyo-based provider of enterprise wireless mesh solutions, today announced that the...

What contingency plans does the company have if it fails to meet the required bid price and faces delisting? How might the notification affect liquidity and short‑term price volatility of PCLA shares? What is the potential timeline for PicoCELA to regain compliance with Nasdaq's minimum bid price requirement?
Symbol: PCLA
Regulation
18 days ago
Read more prnewswire

PicoCELA Inc. Issues Restricted Common Shares to MCC and You Planning

(NASDAQ:PCLA) TOKYO, Aug. 30, 2025 /PRNewswire/ -- On July 28, 2025, PicoCELA Inc. ("PicoCELA" or the "Company,") (NASDAQ: PCLA), a Tokyo-based provider of enterprise wireless mesh solutions, enter...

How does this capital raise compare to PicoCELA's recent financing activities and to similar financing moves by competitors in the enterprise wireless mesh market? What are the terms and conditions of the Share Subscription Agreements, including any lock‑up periods or voting rights, and how might they influence liquidity and control dynamics? How will the issuance of restricted common shares to MCC affect the company's diluted earnings per share and overall valuation?
Symbol: PCLA
Equity
18 days ago
Read more prnewswire

Patagonia Gold Quarter 2, 2025 Financial Results

(PGDC) VANCOUVER, British Columbia, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces its financial results for the quarter ended June 3...

Did the company provide any updated guidance or outlook for 2025, and how might that influence our valuation and trade strategy? How does the reported net loss and cash burn affect Patagonia Gold's liquidity position and need for additional financing? What were the company's production volumes and cash cost per ounce in Q2 2025 compared to the same quarter last year?
Symbol: PGDC
Earnings
18 days ago
Read more globenewswire

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

(NASDAQ:BIIB) LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease aft...

What are the reimbursement, pricing and payer acceptance outlook and potential risks for commercial uptake of the new maintenance dosing regimen? What is the expected market share and revenue potential of the at‑home subcutaneous formulation compared with existing anti‑amyloid therapies and competitors? How will the FDA approval of LEQEMBI® IQLIK™ affect Biogen's (BIIB) stock price in the short and medium term?
Symbol: BIIB
Approval
18 days ago
Read more globenewswire

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

(NASDAQ:BIIB) LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease afte...

How might this at‑home delivery option influence market share dynamics against competitors like Eli Lilly's donanemab and other upcoming Alzheimer's treatments? What pricing strategy and reimbursement landscape can be expected for the subcutaneous injection compared to existing intravenous anti‑amyloid therapies? How will the FDA approval of LEQEMBI® IQLIK™ affect Biogen's projected revenue and earnings forecasts?
Symbol: BIIB
Regulatory
18 days ago
Read more prnewswire